VANDA PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
VANDA PHARMACEUTICALS INC. (VNDA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -0.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -0.70%.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -7.10%, a 123.51% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 30.20%.
- VANDA PHARMACEUTICALS INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was -3.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -0.70% 10-K · filed 2026-02-12 |
| 2024-12-31 | -7.10% 10-K · filed 2026-02-12 |
| 2023-12-31 | 30.20% 10-K · filed 2026-02-12 |
| 2018-12-31 | -3.90% 10-K · filed 2019-02-19 |
| 2017-12-31 | -13.00% 10-K · filed 2019-02-19 |
| 2016-12-31 | -12.50% 10-K · filed 2019-02-19 |
| 2015-12-31 | -5.10% 10-K · filed 2018-02-15 |
| 2014-12-31 | 0.00% 10-K · filed 2017-02-17 |
| 2013-12-31 | 0.00% 10-K · filed 2016-02-12 |
| 2012-12-31 | 1.40% 10-K · filed 2015-03-13 |
| 2011-12-31 | -0.20% 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |